Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Tobacco smoke contains a large number of compounds in the form of metals, volatile gases
and insoluble particles, as well as nicotine, a highly addictive alkaloid. Marijuana is the most …

The P2Y 12 receptor is a key player in platelet activation and represents an effective
pharmacological target for the inhibition of platelet aggregation and prevention of …

Background Coprescribing of clopidogrel and other drugs is common. Available reviews
have addressed the drug–drug interactions (DDIs) when clopidogrel is as an object drug, or …

Background—The degree to which cytochrome P450 (CYP) 2C19 genotype influences the
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …

Background: Cigarette smoking is a well-known risk factor for development of coronary
artery disease (CAD). However, some studies have suggested a “smoker's paradox,” …

Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …

Background Prior studies have found that smokers undergoing thrombolytic therapy for ST‐
segment elevation myocardial infarction have lower in‐hospital mortality than nonsmokers, a …

Peripheral artery disease (PAD) is a major health problem with increased cardiovascular
mortality, morbidity and disabling critical limb threatening ischemia (CLTI) and amputation …